Phase 2 N=8 BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=267 Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 12…
Phase 2 N=103 A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
HER2 Amplified · Advanced Breast Cancer · Human Epidermal Growth Factor Receptor 2 (HER2)
Primary: Clinical Benefit Rate (CBR) — 23.6 percentage of participants
Phase 2 N=26 Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Melanoma
Primary: Progression Free Survival at One Year. — 58 percentage of participants PFS at 1 year
Phase 2 N=162 A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
Iron Deficiency · Anemia · Kidney Disease
Primary: Mean Change In Hemoglobin From Baseline (Day 1) To Week 5 — 0.84; 0.74; 0.89; 0.80 g/dL — p=0.515
Phase 2 N=76 Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Lymphoma, Hodgkin Disease · Lymphoma · Hodgkin Disease
Primary: Progression-free Survival (PFS) — 89.7; 50 percentage of participants
Phase 2 N=39 Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
Lymphoma, Follicular
Primary: Number of Participants With Complete Response at 3 Years — 30 Participants
Phase 2 N=32 Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
Prostate Cancer
Primary: Duration of the First "Off-treatment" Cycle in Patients Who Have Completed One Cycle of Intermittent Androgen Suppression With the Addition of Exisulind. — 39 Weeks
Phase 2 N=18 A Study in Participants With End-Stage Renal Disease
Kidney Failure, Chronic
Primary: Change From Baseline in PRA — -0.706; -2.176; -1.688; -2.353 percentage of population — p=0.324
Phase 2 N=102 Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
Prostate Cancer
Primary: Time to Androgen Independence of Serum Prostate-Specific Antigen (PSA) — 4.0 years
Phase 2 N=20 L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD
Attention Deficit/Hyperactivity Disorder · ADHD
Primary: Change in Adult ADHD Investigator Symptom Rating Scale (AISRS) Score — -6.3 units on a scale
Phase 2 N=11 The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
Neuropathic Pain
Primary: Opioid Use — 101.24; 104.56 morphine equivalent dose
Phase 2 N=100 Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Kaplan Meier Estimate of Progression-Free Survival (PFS) Based on Food and Drug Administration (FDA) Methodology — 2.9; 4.0 months — p=0.1789
Phase 2 N=101 A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
Multiple Myeloma · Solid Tumors
Primary: Number of Participants With Peripheral Neuropathy — 1; 15 participants
Phase 2 N=189 Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus Infection
Primary: Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 — -0.77; -0.89 log10 copies/mL — p=0.46